Literature DB >> 33128851

Noninvasive and minimally invasive techniques for the diagnosis and management of allergic diseases.

Ralf Baumann1,2, Eva Untersmayr3, Ulrich M Zissler4,5, Stefanie Eyerich4,5, Ian M Adcock6, Knut Brockow7, Tilo Biedermann7, Markus Ollert8,9, Adam M Chaker4,5,10, Oliver Pfaar11, Holger Garn12, Ryan S Thwaites6, Alkis Togias13, Marek L Kowalski14, Trevor T Hansel6, Constanze A Jakwerth4,5, Carsten B Schmidt-Weber4,5.   

Abstract

Allergic diseases of the (upper and lower) airways, the skin and the gastrointestinal tract, are on the rise, resulting in impaired quality of life, decreased productivity, and increased healthcare costs. As allergic diseases are mostly tissue-specific, local sampling methods for respective biomarkers offer the potential for increased sensitivity and specificity. Additionally, local sampling using noninvasive or minimally invasive methods can be cost-effective and well tolerated, which may even be suitable for primary or home care sampling. Non- or minimally invasive local sampling and diagnostics may enable a more thorough endotyping, may help to avoid under- or overdiagnosis, and may provide the possibility to approach precision prevention, due to early diagnosis of these local diseases even before they get systemically manifested and detectable. At the same time, dried blood samples may help to facilitate minimal-invasive primary or home care sampling for classical systemic diagnostic approaches. This EAACI position paper contains a thorough review of the various technologies in allergy diagnosis available on the market, which analytes or biomarkers are employed, and which samples or matrices can be used. Based on this assessment, EAACI position is to drive these developments to efficiently identify allergy and possibly later also viral epidemics and take advantage of comprehensive knowledge to initiate preventions and treatments.
© 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Entities:  

Keywords:  anaphylaxis; asthma; atopic dermatitis; food allergy; noninvasive diagnosis

Mesh:

Year:  2021        PMID: 33128851     DOI: 10.1111/all.14645

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  6 in total

Review 1.  Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases.

Authors:  Pavel Kolkhir; Daniel Elieh-Ali-Komi; Martin Metz; Frank Siebenhaar; Marcus Maurer
Journal:  Nat Rev Immunol       Date:  2021-10-05       Impact factor: 53.106

2.  A Non-Invasive Neonatal Signature Predicts Later Development of Atopic Diseases.

Authors:  Youssouf Sereme; Moïse Michel; Soraya Mezouar; Cheick Oumar Guindo; Lanceï Kaba; Ghiles Grine; Thibault Mura; Jean-Louis Mège; Tu Anh Tran; Pierre Corbeau; Anne Filleron; Joana Vitte
Journal:  J Clin Med       Date:  2022-05-12       Impact factor: 4.964

Review 3.  Role of Respiratory Epithelial Cells in Allergic Diseases.

Authors:  Constanze A Jakwerth; Jose Ordovas-Montanes; Simon Blank; Carsten B Schmidt-Weber; Ulrich M Zissler
Journal:  Cells       Date:  2022-04-20       Impact factor: 7.666

4.  Profiling the Atopic Dermatitis Epidermal Transcriptome by Tape Stripping and BRB-seq.

Authors:  Tu Hu; Tanja Todberg; Daniel Andersen; Niels Banhos Danneskiold-Samsøe; Sofie Boesgaard Neestrup Hansen; Karsten Kristiansen; David Adrian Ewald; Susanne Brix; Joel Correa da Rosa; Ilka Hoof; Lone Skov; Thomas Litman
Journal:  Int J Mol Sci       Date:  2022-05-30       Impact factor: 6.208

Review 5.  Role of microRNAs in type 2 diseases and allergen-specific immunotherapy.

Authors:  Constanze A Jakwerth; Hannah Kitzberger; Dimitrii Pogorelov; Annika Müller; Simon Blank; Carsten B Schmidt-Weber; Ulrich M Zissler
Journal:  Front Allergy       Date:  2022-09-12

Review 6.  Extracellular Vesicles and Asthma-More Than Just a Co-Existence.

Authors:  Bilal Alashkar Alhamwe; Daniel P Potaczek; Sarah Miethe; Fahd Alhamdan; Lukas Hintz; Arslan Magomedov; Holger Garn
Journal:  Int J Mol Sci       Date:  2021-05-07       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.